Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Boston Scientific posts strong Q2 growth despite U.S. challenges, stock now valued attractively.
BSX
$50.60
+$0.14 +0.28%

Boston Scientific posts strong Q2 growth despite U.S. challenges, stock now valued attractively.

Company Fundamentals
11 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Boston Scientific reported solid Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth, driven by strong international demand, particularly in electrophysiology and WATCHMAN devices. Despite facing growth headwinds in the U.S., the company’s robust free cash flow of $1.29 billion in Q2 supports ongoing innovation, acquisitions, and potential share buybacks. The stock has been heavily sold off due to lowered guidance but now trades at attractive valuations compared to peers, leading to a strong buy rating at current levels.

More News (BSX)

Boston Scientific to present at Wells Fargo Healthcare Conference and report Q3 2026 results in October

Boston Scientific to present at Wells Fargo Healthcare Conference and report Q3 2026 results in October

Boston Scientific Corporation announced it will participate in Wells Fargo's 21st Annual Healthcare Conference on September 10, 2026, with CEO Mike Mahoney and CMO Kenneth Stein leading a Q&A session. The company will also release its financial resul...

Company Fundamentals
Neutral
21 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App